Randomized phase II trial to evaluate the effectiveness of azacitidine for low risk MDS
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
Price : $35 *
At a glance
- Drugs Azacitidine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 02 Jun 2015 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
- 17 Jan 2014 Status changed from not yet recruiting to recruiting as per University Hospital Medical Information Network - Japan record.
- 14 Aug 2013 New trial record